Edgewise Therapeutics Inc. (EWTX), a biopharmaceutical company focused on muscle diseases, has two key data readouts for its lead drug candidate, Sevasemten, expected this quarter.Sevasemten is an oral fast skeletal myosin inhibitor designed to protect muscle against contraction-induced damage under development for the treatment of Duchenne muscular dystrophy and Becker muscular dystrophy. Duchenn...
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.